atrophic gastritis and gastric intestinal metaplasia

in review 5 min read Updated 2026-11-19
atrophic gastritis and gastric intestinal metaplasia

Two routes to the same atrophic stomach: H. pylori (antrum first, spreads proximally; most common) and autoimmune (corpus-only, antrum spared). GIM on a biopsy almost always means atrophy is present. Every patient: test for H. pylori, eradicate, confirm cure (AGA strong). Corpus atrophy → check iron and B12; autoimmune → also TSH, and endoscopy to look for type 1 gastric NETs. Surveillance is not routine for incidental GIM (AGA, very low certainty); offer it by shared decision when risk is high: extensive or incomplete GIM, first-degree relative with gastric cancer, immigrant from a high-incidence region (East Asia, Latin America, Eastern Europe). Advanced atrophy → endoscopy about every 3 years.


the two patterns

flowchart LR
  A[H. pylori chronic gastritis] --> B[atrophy: antrum and incisura first]
  B --> C[intestinal metaplasia]
  C --> D[dysplasia]
  D --> E[intestinal-type gastric adenocarcinoma]
  F[autoimmune: anti-parietal cell + anti-IF] --> G[corpus atrophy, antrum spared]
  G --> H[achlorhydria → ↑gastrin → ECL hyperplasia]
  H --> I[type 1 gastric NET]
  G --> J[iron deficiency, then B12 deficiency / pernicious anaemia]
  G --> C
H. pylori atrophic gastritisautoimmune gastritis
distributionantrum → spreads to corpuscorpus/fundus only, antrum spared
whoH. pylori-endemic regions, older, immigrants from high-risk countrieswomen, other autoimmunity (up to ⅓ of autoimmune thyroid disease), T1DM
gastrinnormal or modestly raisedmarkedly raised (loss of acid feedback)
main risksadenocarcinomairon and B12 deficiency, type 1 NET, adenocarcinoma
serologyH. pylori positive (may have cleared)anti-parietal cell (sensitive, not specific); anti-intrinsic factor (specific, <30% sensitive)
  • mechanism behind the deficiencies: acid is needed to release dietary non-haem iron; parietal cells make intrinsic factor. Iron deficiency appears years before B12 deficiency (up to half of corpus-predominant AG)
  • pernicious anaemia = end-stage autoimmune gastritis
  • progression to adenocarcinoma ~0.1–0.3%/year, similar to non-dysplastic Barrett’s oesophagus; higher with extent, severity and IM

the first endoscopy decides the risk

  • diagnosis is histological: endoscopic pallor, visible vessels and lost folds are suggestive but subtle
  • updated Sydney protocol: ≥5 biopsies, antrum/incisura and corpus in separate jars. Random biopsies in one jar can’t stage extent or separate the two patterns, which is why surveillance decisions after a single-jar “GIM” are hard
  • OLGA/OLGIM stage III–IV = advanced (extensive, severe) → highest risk. Few North American pathologists report it routinely
  • incomplete (colonic-type) GIM ~3× and extensive GIM ~2× the cancer risk of complete or antrum-limited GIM; first-degree relative with gastric cancer ~4.5×
  • autoimmune pattern on histology → anti-parietal cell + anti-intrinsic factor antibodies to support it

management

every patient

  • H. pylori: test (serology alone can’t confirm active infection) → eradicate → confirm cure with a non-serological test (UBT or stool antigen) → peptic ulcer disease and H. pylori
    • eradication lowers gastric cancer incidence ~32% (RR 0.68; trials of infected people with and without GIM); the GIM-only subgroup is underpowered (RR 0.76, CI crosses 1). Atrophy can regress after eradication; established IM usually doesn’t
  • corpus involvement (either cause): ferritin, B12; and conversely, think of atrophic gastritis in unexplained iron or B12 deficiency → iron deficiency, anaemia
    • the cause doesn’t go away: replacement is long-term, and oral iron absorbs poorly without acid

autoimmune gastritis

  • TSH at diagnosis and periodically; low threshold to look for T1DM and Addison’s when symptoms fit
  • endoscopy to screen for type 1 NETs (incidence ~0.4–0.7%/year with corpus atrophy)
    • <1 cm → endoscopic resection, then endoscopy every 1–2 years by burden
    • 1–2 cm → EUS for depth and nodes
    • 2 cm, beyond submucosa or node-positive → surgery (metastasis <10% when ≤2 cm, ~20% when larger)

  • new pernicious anaemia without a recent endoscopy → endoscopy with mapping biopsies (ASGE: within 6 months; cancer risk highest in the first year). Surveillance interval after that: individualised (ESGE 3–5 years)

surveillance for gastric cancer

situationdefaultguideline
incidental GIM, no high-risk featuresno routine surveillanceAGA 2020, conditional, very low certainty
GIM + incomplete type, extensive, first-degree relative, or high-incidence ancestry / immigrationshared decision for surveillance; if chosen, endoscopy with mapping biopsies every 3–5 yearsAGA 2020
GIM + nodularity, poor-quality index scope, or single-jar biopsies in a high-risk personrepeat endoscopy within 1 year to map extent, subtype, exclude prevalent cancerAGA 2020 (patient preference; AGA advises against routine short-interval repeat for risk stratification alone)
advanced AG (OLGA/OLGIM III–IV, extensive)consider endoscopy ~every 3 years (individualised)AGA 2021
dysplasiaGI referral for resection; outside this note—

No study compares surveillance with no surveillance for outcomes; the case rests on cohort data (~1.6% ten-year cancer risk with GIM overall) and on high-incidence-country data. In Canada, much of the higher risk sits in immigrants from East Asia, Latin America and Eastern Europe, which is where a surveillance discussion is worth having.


key points

  • GIM is found in ~5% of upper endoscopies; most will never progress
  • ASGE suggests stopping surveillance after two consecutive endoscopies without dysplasia
  • pepsinogen I/II testing is used for screening in East Asia; not available routinely in Canada
  • population gastric cancer screening isn’t recommended in low-incidence countries → cancer screening — Canadian guidelines

Prepared 2026-11-19. Not yet verified — check every number against the sources.

Key references

Suggest a correction atrophic gastritis and gastric intestinal metaplasia